Prince Pharmaceutical Co., Ltd. (TPEX:6935)
Taiwan
· Delayed Price · Currency is TWD 29.00
0.00 (0.00%)
Apr 29, 2026, 1:45 PM CST
Prince Pharmaceutical Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Cash & Equivalents | 152.62 | 102.8 | 122.57 | 71.96 | 72.5 | Upgrade
|
| Cash & Short-Term Investments | 152.62 | 102.8 | 122.57 | 71.96 | 72.5 | Upgrade
|
| Cash Growth | 48.46% | -16.12% | 70.33% | -0.74% | 27.02% | Upgrade
|
| Accounts Receivable | 197.13 | 116.63 | 108.7 | 72.65 | 62.44 | Upgrade
|
| Receivables | 197.13 | 116.63 | 108.7 | 72.65 | 62.44 | Upgrade
|
| Inventory | 207.58 | 141.47 | 142.12 | 149.86 | 125.44 | Upgrade
|
| Prepaid Expenses | 2.76 | - | - | - | - | Upgrade
|
| Other Current Assets | 0.81 | 4.22 | 18.01 | 7.22 | 14.91 | Upgrade
|
| Total Current Assets | 560.89 | 365.13 | 391.39 | 301.68 | 275.29 | Upgrade
|
| Property, Plant & Equipment | 932.72 | 973.6 | 999.83 | 969.34 | 979.79 | Upgrade
|
| Other Intangible Assets | 0.5 | 0.45 | 1.3 | 1.51 | 2.02 | Upgrade
|
| Long-Term Deferred Tax Assets | 2.75 | 2.29 | 3.83 | 3.26 | 15.85 | Upgrade
|
| Other Long-Term Assets | 6.62 | 6.78 | 14.59 | 28.49 | 17.69 | Upgrade
|
| Total Assets | 1,503 | 1,348 | 1,411 | 1,304 | 1,291 | Upgrade
|
| Accounts Payable | 163.24 | 108.06 | 84.83 | 55.37 | 68.46 | Upgrade
|
| Accrued Expenses | 54.08 | - | - | - | - | Upgrade
|
| Short-Term Debt | 30 | 30 | 30 | 30 | 60 | Upgrade
|
| Current Portion of Long-Term Debt | 33.14 | 32.35 | 31.76 | 31.43 | 16.91 | Upgrade
|
| Current Portion of Leases | 4.93 | 8.07 | 5.01 | 6.97 | 3.19 | Upgrade
|
| Current Income Taxes Payable | 8.84 | - | 4.35 | - | - | Upgrade
|
| Current Unearned Revenue | 4.3 | 5.45 | 2.62 | 14.78 | 10.91 | Upgrade
|
| Other Current Liabilities | 11.38 | 50.79 | 53.38 | 51.61 | 41.67 | Upgrade
|
| Total Current Liabilities | 309.91 | 234.71 | 211.94 | 190.16 | 201.14 | Upgrade
|
| Long-Term Debt | 234.13 | 267.27 | 299.49 | 330.92 | 362.06 | Upgrade
|
| Long-Term Leases | 119.83 | 123.11 | 124.1 | 123.78 | 123.83 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 0.95 | 1.1 | 0.93 | 1.05 | 0.74 | Upgrade
|
| Total Liabilities | 664.81 | 626.19 | 636.47 | 645.91 | 687.77 | Upgrade
|
| Common Stock | 374.1 | 366.05 | 361.93 | 331.93 | 331.93 | Upgrade
|
| Additional Paid-In Capital | 368.67 | 363.93 | 348.49 | 282.22 | 279.29 | Upgrade
|
| Retained Earnings | 95.91 | -7.92 | 53.81 | 44.23 | -8.36 | Upgrade
|
| Comprehensive Income & Other | - | - | 10.24 | - | - | Upgrade
|
| Shareholders' Equity | 838.68 | 722.06 | 774.47 | 658.38 | 602.87 | Upgrade
|
| Total Liabilities & Equity | 1,503 | 1,348 | 1,411 | 1,304 | 1,291 | Upgrade
|
| Total Debt | 422.03 | 460.8 | 490.36 | 523.11 | 565.99 | Upgrade
|
| Net Cash (Debt) | -269.41 | -357.99 | -367.79 | -451.15 | -493.49 | Upgrade
|
| Net Cash Per Share | -7.29 | -9.79 | -10.06 | -13.54 | -14.87 | Upgrade
|
| Filing Date Shares Outstanding | 36.61 | 36.61 | 36.19 | 33.19 | 33.19 | Upgrade
|
| Total Common Shares Outstanding | 36.61 | 36.61 | 36.19 | 33.19 | 33.19 | Upgrade
|
| Working Capital | 250.98 | 130.42 | 179.45 | 111.52 | 74.15 | Upgrade
|
| Book Value Per Share | 22.91 | 19.73 | 21.40 | 19.83 | 18.16 | Upgrade
|
| Tangible Book Value | 838.17 | 721.61 | 773.16 | 656.86 | 600.85 | Upgrade
|
| Tangible Book Value Per Share | 22.90 | 19.71 | 21.36 | 19.79 | 18.10 | Upgrade
|
| Land | 102.92 | 102.92 | 102.92 | 102.92 | 102.92 | Upgrade
|
| Buildings | 593.57 | 580.78 | 580.78 | 578.84 | 578.62 | Upgrade
|
| Machinery | 462 | 462.94 | 441.82 | 365.91 | 336.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.